Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | ALDH3A1 | P30838 | 3/20 | 0.44 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.44 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 4/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.39 |
| ▸ | S100A4 | P26447 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28026697 | 0.79 | PARK7 (0.53) | ACHEALDH1A1ALDH3A1ALDH2CUL4A | |
| SCHEMBL7233659 | 0.77 | CES1 (0.65) | ACHEALDH1A1ALDH3A1ALDH2CES1 | |
| SCHEMBL28417115 | 0.74 | ALDH1A1 (0.57) | ACHEALDH1A1ALDH3A1ALDH2CUL4A | |
| SCHEMBL15206958 | 0.74 | ALDH1A1 (0.78) | ACHEALDH1A1ALDH3A1ALDH2CES1 | |
| SCHEMBL16075218 | 0.73 | ALDH1A1 (0.47) | ACHEALDH1A1ALDH3A1ALDH2CUL4A | |
| SCHEMBL16064931 | 0.73 | ALDH1A1 (0.47) | ACHEALDH1A1ALDH3A1ALDH2CUL4A | |
| SCHEMBL16064397 | 0.73 | ALDH1A1 (0.47) | ACHEALDH1A1ALDH3A1ALDH2CUL4A | |
| SCHEMBL28026703 | 0.73 | ACHE (0.67) | ACHEALDH1A1ALDH3A1ALDH2CES1 | |
| SCHEMBL26621713 | 0.72 | PARK7 (0.45) | ACHEALDH1A1ALDH3A1ALDH2CHRM5 | |
| SCHEMBL28417285 | 0.72 | CES1 (0.65) | ACHEALDH1A1ALDH3A1ALDH2CUL4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | ACHE 693/4885ALDH1A1 916/4885ALDH3A1 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.